1 active not recruiting, 1 terminated, 1 withdrawn. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 1, Terminated 1, Withdrawn 1 |
Follow Antonio Fojo: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer Ponatinib - Medullary Thyroid Cancer | Phase 2 | Withdrawn | Antonio Fojo | 2019-07-26 | 2021-10-13 | |
| LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA) Lanreotide - Paraganglioma, Pheochromocytoma | Phase 2 | Active not recruiting | Antonio Fojo | 10 | 2019-06-17 | 2026-03-02 |
| Entinostat Neuroendocrine (NE) Tumor Entinostat - Neuroendocrine Tumors | Phase 2 | Terminated | Antonio Fojo | 5 | 2017-12-13 | 2026-03-02 |
Carcinoma, Medullary (1) · Neuroendocrine Tumors (1) · Paraganglioma (1) · Pheochromocytoma (1) · Recurrence (1)
entinostat (1) · lanreotide (1) · ponatinib (1)
United States (2)